{
    "clinical_study": {
        "@rank": "6417", 
        "arm_group": [
            {
                "arm_group_label": "(8 mg) RBP-6000:  50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on Subutex 8 mg.  During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals."
            }, 
            {
                "arm_group_label": "(12 mg) RBP-6000:  100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals"
            }, 
            {
                "arm_group_label": "(24 mg) RBP-6000:  200 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.\nParticipants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) will have the option to participate in the Positron Emission Tomography (PET) Pilot substudy.  In the PET Pilot sub-study participants will remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
            }, 
            {
                "arm_group_label": "(8 mg) RBP-6000:  100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals."
            }, 
            {
                "arm_group_label": "(14 mg) RBP-6000:  200 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.\nParticipants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) will have the option to participate in the Positron Emission Tomography (PET) Pilot substudy.  In the PET Pilot sub-study participants will remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
            }, 
            {
                "arm_group_label": "(8-24 mg) RBP-6000:  300 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label study in treatment seeking opioid-dependent subjects for safety,\n      tolerability, pharmacokinetics, efficacy markers, and opioid receptor availability of\n      subcutaneous injections of depot buprenorphine after induction and stabilization of\n      treatment seeking subjects onto Subutex."
        }, 
        "brief_title": "Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Related Disorder", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects\n\n          -  Agree not to take any buprenorphine products other than those administered for the\n             current study throughout participation in the study\n\n          -  Body mass index (BMI) of >18.0 to < 33.0 kg/m\n\n        Exclusion Criteria:\n\n          -  Participants with a current diagnosis requiring chronic opioid treatment\n\n          -  Participants with a history of risk factors of Torsades de Pointes (e.g., heart\n             failure, hypokalemia, family history of Long QT Syndrome) or an ECG demonstrating a\n             Fridericia's corrected QT interval (QTcF) >450 msec in males and QTcF > 470 in\n             females at screening\n\n          -  Abuse of buprenorphine or use of buprenorphine within 14 days of informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738503", 
            "org_study_id": "RB-US-12-0005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "(8 mg) RBP-6000:  50 mg", 
                    "(12 mg) RBP-6000:  100 mg", 
                    "(24 mg) RBP-6000:  200 mg", 
                    "(8 mg) RBP-6000:  100 mg", 
                    "(14 mg) RBP-6000:  200 mg", 
                    "(8-24 mg) RBP-6000:  300 mg"
                ], 
                "description": "18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL\u00ae Delivery System.  Each injection of RBP-6000 is separated by a minimum of 28 days and will be given on alternate sides of the participant's abdomen.", 
                "intervention_name": "RBP-6000", 
                "intervention_type": "Drug", 
                "other_name": "buprenorphine"
            }, 
            {
                "arm_group_label": [
                    "(8 mg) RBP-6000:  50 mg", 
                    "(12 mg) RBP-6000:  100 mg", 
                    "(24 mg) RBP-6000:  200 mg", 
                    "(8 mg) RBP-6000:  100 mg", 
                    "(14 mg) RBP-6000:  200 mg", 
                    "(8-24 mg) RBP-6000:  300 mg"
                ], 
                "description": "Participants were inducted and stabilized (over a 14-day period) on SUBUTEX at doses of 8 mg, 12 mg, 14 mg, or 8-24 mg.  Tablets are placed under the tongue until dissolved.", 
                "intervention_name": "Subutex", 
                "intervention_type": "Drug", 
                "other_name": "Buprenorphine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Opioid Dependence, Buprenorphine, Depot, SUBUTEX, RBP-6000", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "last_name": "Bradley D Vince, DO", 
                "phone": "913-696-1601"
            }, 
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66212"
                }, 
                "name": "Vince and Associates Clinical Research"
            }, 
            "investigator": [
                {
                    "last_name": "Bradley D. Vince, DO", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Steven G Hull, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "An Open-Label, Multicenter, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Treatment Seeking Opioid-Dependent Subjects", 
        "overall_contact": {
            "last_name": "Heather D Sutton", 
            "phone": "804-423-8961"
        }, 
        "overall_official": {
            "affiliation": "Vince and Associates Clinical Research", 
            "last_name": "Bradley D Vince, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compare the steady state PK of buprenorphine and norbuprenorphine after SC doses of RBP-6000 relative to the corresponding SUBUTEX doses", 
            "safety_issue": "No", 
            "time_frame": "Days -13 to -1 (Subutex treatment), Days 1-113 (RBP-6000 treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline To Day 113 in the Clinical Opiate Withdrawal Scale (COWS)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (pre-treatment), Day 113"
            }, 
            {
                "measure": "Change from Baseline To Day 113 in the Subjective Opiate Withdrawal Scale (SOWS)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (pre-treatment), Day 113"
            }, 
            {
                "measure": "Change from Baseline To Day 113 in the Opioid Craving Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (pre-treatment), Day 113"
            }, 
            {
                "description": "The total of the Clinical Global Impression - Severity scale (CGIS) and the Clinical Global Impression - Improvement scale (CGI-I) scores .", 
                "measure": "Change from Baseline To Day 113 in the Clinical Global Impression Total Scores.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (pre-treatment), Day 113"
            }, 
            {
                "measure": "Change from Baseline To Day 113 in the Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (pre-treatment), Day 113"
            }
        ], 
        "source": "Reckitt Benckiser Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}